Bristol-Myers Squibb (BMY) offers Eliquis free to Medicaid patients under new pricing pact. This move is part of a broader effort to improve cardiovascular care, expand patient access, and reduce costs for Americans. The company was also part of a group of drugmakers who agreed to lower prices voluntarily in December.

Morgan Stanley raised Bristol-Myers Squibb’s price target to $37 from $36 on December 12. The company focuses on developing medicines for serious diseases worldwide, with a pipeline spanning oncology, cardiovascular care, immunology, and other conditions. Analysts believe that as policy concerns ease, stock selection may become more important.

Despite the potential of BMY as an investment, some believe that certain AI stocks offer greater upside potential with less downside risk. If you are interested in an undervalued AI stock that could benefit from Trump-era tariffs and the onshoring trend, check out the best short-term AI stock in a free report. No promotional or marketing language included.

Read more at Yahoo Finance: Bristol-Myers (BMY) Offers Eliquis Free to Medicaid Patients Under New Pricing Pact